It's Specialism, not Size, that Counts, says Schering AG's Hubertus Erlen
Executive Summary
The chairman and CEO of Germany's Schering isn't fazed by the drug industry's latest mega-merger: Pfizer's proposed acquisition of Pharmacia. By sticking to sectors that are expertise- rather than size-driven, he's confident that the mid-sized group can continue growing and avoid many of the problems facing its larger peers.
You may also be interested in...
Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?
The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.
Pandemic Spotlights Tensions Between Profit And Philanthropy
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Virtual Health Care: Where Does This Leave Pharma Marketing?
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.